Piramal Pharma Limited (PPLPHARMA) AI Stock Analysis

• Market Cap: ₹259.80B
• Dividend Yield: 0.07%
• Average Volume (3M): 207.00K
• Price to Earnings (P/E): 268.4
• Beta (1Y): 0.69
• Revenue Growth: 9.08%
• EPS Growth: 249.08%
• Country: IN
• Employees: 6,719
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.80
• Shares Outstanding: 1,329,248,200
• 10 Day Avg. Volume: 176,334
• 30 Day Avg. Volume: 207,003
• PEG Ratio: 0.84
• Price to Book (P/B): 3.72
• Price to Sales (P/S): 3.30
• P/FCF Ratio: 132.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹271.67
• Price Target Upside: 39.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 53 Neutral
• Price Target: ₹198.00 ▲(1.30% Upside)

Piramal Pharma Limited's stock score is primarily impacted by its strong financial performance in terms of revenue growth and gross margins. However, the high P/E ratio and low dividend yield suggest overvaluation, while technical indicators point to a bearish trend. The lack of earnings call data and corporate events further limits the assessment.

Piramal Pharma Limited Business Overview & Revenue Model

Company Description

Piramal Pharma Limited (PPLPHARMA) is a leading global pharmaceutical company based in India, operating under the Piramal Group. The company focuses on developing and manufacturing a wide range of pharmaceutical products, including branded and generic formulations, active pharmaceutical ingredients (APIs), and contract development and manufacturing services (CDMO). PPLPHARMA is committed to providing innovative healthcare solutions across various therapeutic areas such as oncology, cardiovascular, and central nervous system disorders, leveraging its extensive research and development capabilities.

How the Company Makes Money

Piramal Pharma Limited generates revenue through multiple streams, primarily from the sale of pharmaceutical products, including both branded and generic medications. The company has a significant presence in the contract development and manufacturing services (CDMO) sector, providing custom manufacturing solutions for other pharmaceutical companies, which contributes to its revenue. Additionally, PPLPHARMA earns income through licensing agreements and collaborations with other firms, enhancing its market reach and product portfolio. Strategic partnerships and alliances with healthcare organizations further bolster its earnings by broadening access to diverse markets and increasing the scale of operations.

Piramal Pharma Limited Financial Statement Overview

Summary

Piramal Pharma Limited shows strong revenue growth and a solid balance sheet with manageable debt levels. However, inconsistent net profit margins and fluctuating free cash flow indicate challenges in maintaining stable profitability and cash generation.

Income Statement

Piramal Pharma Limited has shown a steady increase in revenue over the years, indicating a positive growth trajectory. The gross profit margin is robust, standing at approximately 64.7% in 2025. However, net profit margins have been inconsistent, with significant fluctuations, highlighting potential volatility in bottom-line profitability. EBIT margin improved significantly in 2025, suggesting better operational efficiency, but the EBITDA margin remains moderately low, indicating room for improvement in operational cash flow generation.

Balance Sheet

The company maintains a solid equity base, with a debt-to-equity ratio of 0.60 in 2025, reflecting a balanced capital structure and manageable leverage. Return on Equity (ROE) shows variability, indicating fluctuating profitability relative to shareholder investments. The equity ratio is healthy, suggesting a stable asset-financing structure primarily through equity, which reduces financial risk.

Cash Flow

Operating cash flow has been relatively stable, but free cash flow has seen significant fluctuations, indicating potential issues with capital expenditure management. The operating cash flow to net income ratio in 2025 is notably high, suggesting effective cash conversion from profits. However, the free cash flow growth rate has been inconsistent, raising concerns about sustainable cash generation capabilities.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	91.34B	91.51B	81.71B	70.82B	65.59B	58.87B
Gross Profit	66.47B	59.20B	49.09B	10.98B	13.80B	38.13B
EBITDA	14.86B	14.04B	13.67B	8.46B	12.60B	12.97B
Net Income	980.70M	911.30M	178.20M	-1.86B	3.76B	5.71B
Balance Sheet
Total Assets	0.00	156.78B	153.12B	145.23B	127.97B	57.57B
Cash, Cash Equivalents and Short-Term Investments	4.08B	5.21B	5.02B	6.60B	3.79B	1.62B
Total Debt	0.00	48.56B	47.10B	56.37B	41.28B	1.74B
Total Liabilities	-81.25B	75.52B	74.00B	77.49B	61.00B	16.56B
Stockholders Equity	81.25B	81.25B	79.11B	67.73B	66.97B	41.01B
Cash Flow
Free Cash Flow	0.00	2.28B	2.92B	-4.81B	-1.23B	-233.90M
Operating Cash Flow	0.00	8.92B	10.05B	4.84B	7.66B	347.20M
Investing Cash Flow	0.00	-4.77B	-4.34B	-13.39B	-18.12B	-43.83B
Financing Cash Flow	0.00	-4.41B	-4.22B	8.18B	7.94B	44.94B

Piramal Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 195.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PPLPHARMA, the sentiment is Negative. The current price of 195.45 is below the 20-day moving average (MA) of 198.79, below the 50-day MA of 195.71, and below the 200-day MA of 211.55, indicating a bearish trend. The MACD of -0.48 indicates Positive momentum. The RSI at 48.09 is Neutral, neither overbought nor oversold. The STOCH value of 53.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PPLPHARMA.

Piramal Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTRAZEN	70 Outperform	₹234.95B	127.14	―	0.34%	33.69%	91.28%
GLAND	69 Neutral	₹319.55B	41.77	―	0.93%	-2.34%	6.64%
PFIZER	69 Neutral	₹238.83B	29.54	―	0.67%	4.35%	32.89%
JBCHEPHARM	66 Neutral	₹261.12B	37.87	―	0.93%	11.56%	16.30%
IPCALAB	63 Neutral	₹335.27B	42.78	―	0.30%	11.49%	35.00%
PPLPHARMA	53 Neutral	₹259.80B	268.35	―	0.07%	9.08%	249.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Piramal Pharma Limited Corporate Events

Piramal Pharma Limited’s 5th AGM: Resolutions Passed and Shareholder Engagement Enhanced

Piramal Pharma Limited successfully conducted its 5th Annual General Meeting (AGM) on July 30, 2025, via video conference, ensuring compliance with regulatory guidelines. All proposed resolutions were passed with the requisite majority, demonstrating strong shareholder support and effective governance practices. The AGM proceedings were webcast for transparency, and e-voting facilities were provided to facilitate shareholder participation, reflecting the company’s commitment to leveraging technology for stakeholder engagement.

Piramal Pharma Receives ESG Rating from NSE Sustainability

Piramal Pharma Limited has been assigned an ESG Rating of ’61’ for the fiscal year 2023-24 by NSE Sustainability Ratings and Analytics Limited. This rating, which the company did not solicit, reflects the company’s performance in environmental, social, and governance aspects based on publicly available data. The rating could impact the company’s reputation and stakeholder perceptions regarding its commitment to sustainable practices.